Compare · GLP-1 agonist
Amycretin vs CagriSema
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Amycretin | CagriSema | |
|---|---|---|
| Evidence | 6/10 | 9/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere. | An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide. |
| Full profile → | Full profile → |
Amycretin
Amycretin is an experimental drug from Novo Nordisk. Its early weight-loss numbers have turned heads, which is exactly why it keeps popping up on peptide forums and gray-market menus. It is a single molecule (one compound, not a blend) that switches on two receptors at the same time — the GLP-1…
CagriSema
CagriSema is one of the most heavily studied combination products in the pipeline of new obesity drugs. It's also a good example of why "strong trial data" and "proven, approved, and better than the alternatives" are not the same thing. It's a once-weekly shot that packs two peptides into a single…